SPY755.35+0.72%QQQ685.99+1.66%BTC/USD73,750.00+0.07%DIA521.60−0.02%GLD371.26+0.51%TLT80.69−0.23%

Premium Services

Theriva Biologics Inc

TOVXAMEX

Trade with Public

Trade with Public

$0.1542

-0.0116-7%

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Theriva Biologics (TOVX) Stock Price Target 2026

The average analyst price target for Theriva Biologics is $1. The one analyst covering it rates it Buy. The latest change came on Mar 31, 2026, when Maxim Group upgraded Theriva Biologics from Hold to Buy with a $1 price target.

The Average Analyst Price Target for Theriva Biologics is $1.

Price Target Range — 2 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$1

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Theriva Biologics Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Mar 31, 2026	Maxim Group	Jason McCarthy	Upgrade	Hold→Buy	$1
May 8, 2025	Maxim Group	Jason McCarthy	Downgrade	Buy→Hold	—
Nov 13, 2024	Maxim Group	Jason McCarthy	PT Cut	Buy	$25→$6

Analyst Ratings News

PRO
Maxim Group Upgrades Theriva Biologics to Buy, Announces $1 Price Target

Maxim Group analyst Jason McCarthy upgrades Theriva Biologics (AMEX:TOVX) from Hold to Buy and announces $1 price target.

Benzinga Newsdesk

Stock Market Today: Nasdaq, S&P 500 Futures Gain On 3rd Day Of Government Shutdown—Rumble, Riggeti, Kodiak In Focus (UPDATED)

U.S. stock futures advanced on Friday following Thursday's record advances. Futures of major benchmark indices were higher.

Rishabh Mishra

This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

Avi Kapoor

PRO
Maxim Group Downgrades Theriva Biologics to Hold

Maxim Group analyst Jason McCarthy downgrades Theriva Biologics (AMEX:TOVX) from Buy to Hold.

Benzinga Newsdesk

PRO
Maxim Group Maintains Buy on Theriva Biologics, Lowers Price Target to $6

Maxim Group analyst Jason McCarthy maintains Theriva Biologics (AMEX:TOVX) with a Buy and lowers the price target from $25 to $6.

Benzinga Newsdesk